Furthermore, multiple subgroup analyses from the FINEARTS-HF study exhibited that finerenone’s efficacy in patients with HF and LVEF ≥ 40% remained consistent across different baseline characteristics, including baseline LVEF, NT-proBNP, renal function, blood glucose levels, history of atrial fibrillation, and use of SGLT2is (Solomon et al., 2024). This evidence concerns the gene NPPB and hydrops fetalis.